Source comparison
Can You Take MOTS-c Orally: MOTS-c Administration Routes Comparison
This table compares administration methods based on peer-reviewed pharmacokinetic data and research protocol standards: Subcutaneous Injection 98–100% 4–6 hours sustained Minimal. Bypasses first-pass High. Exact mg dosing Systemic distribution to all target ti
This comparison does not assign a generated winner or score.
- This table compares administration methods based on peer-reviewed pharmacokinetic data and research protocol standards:
- Subcutaneous Injection
- 98–100%
- 4–6 hours sustained
- Minimal. Bypasses first-pass
- High. Exact mg dosing
- Systemic distribution to all target tissues
- Gold standard in research protocols. Delivers intact peptide with predictable pharmacokinetics and reproducible dosing across studies
- Oral (Standard)
- 3–8%
- 30–45 minutes transient
- Gastric proteases + hepatic first-pass
- Low. High variability
- Limited. Mostly GI tract exposure
- Not viable for systemic metabolic signaling. 92–97% degradation before absorption makes precise dosing impossible
- Oral (Enteric-Coated)
- 8–12% (estimated)
- 45–90 minutes transient
- Pancreatic proteases + hepatic first-pass
- Moderate. Delayed but still variable
- Primarily small intestine
- Delays degradation but doesn't prevent it. Still loses 88–92% of the dose and lacks sustained plasma levels
- Intranasal
- 15–25% (preclinical only)
- 2–3 hours
- Nasal mucosa enzymatic activity
- Moderate. Absorption variability
- CNS-preferential via olfactory pathway
- Experimental only. No human trials; may offer CNS targeting but systemic bioavailability remains poor
- Intravenous
- 100%
- Immediate peak, 1–2 hour clearance
- Renal filtration
- Very high. Direct plasma delivery
- Immediate systemic distribution
- Not practical for research use. Requires clinical administration and offers no advantage over subcutaneous for sustained signaling